Oral Berotralstat Effective and Safe for HAE Prevention in Young Children: Study
A newly published retrospective cohort study (APeX‑P trial) in Journal of Allergy and Clinical Immunology: In Practice found that oral berotralstat—a once‑daily plasma kallikrein inhibitor—was well tolerated and highly effective in reducing hereditary angioedema (HAE) attack rates in children aged 2–11 years. Among the 29 pediatric participants (median age 8), berotralstat led to early and […]